Gerresheimer Reports Significant Growth After Acquiring Bormioli Pharma

Gerresheimer Reports Significant Growth After Acquiring Bormioli Pharma



In the report released on April 11, 2025, Gerresheimer AG showcased impressive financial results influenced by the recent acquisition of Bormioli Pharma, which was finalized in 2024. The innovative company, a leader in providing systems and solutions for the pharmaceutical, biotechnology, and cosmetics sectors, achieved a notable revenue increase of 11.6%, totaling €520.1 million compared to €466.1 million in the same quarter of the previous year. Similarly, the adjusted EBITDA rose by 13.1%, reaching €91.5 million.

However, it is important to note that on an organic basis, when excluding the impact of Bormioli Pharma, there was a decline in revenue by 6.5% and a drop in adjusted EBITDA by 9.3%. This downturn was primarily attributed to a revenue shift in the syringe business, alongside reduced demand for molded glass products related to the cosmetics industry. Despite these challenges, Gerresheimer's adjusted EBITDA margin remained fundamentally stable at 17.6%, marking an improvement from 17.4% in Q1 2024.

As part of their strategy, Gerresheimer's CEO, Dietmar Siemssen, highlighted that the acquisition has fortified their market standing and allowed for a significant enhancement in both revenue and earnings capabilities. The company remains optimistic about future growth, reiterating its predictions of a 3-5% organic revenue growth and an adjusted EBITDA margin climbing to approximately 22% in 2025.

Breakdown of Business Segments



Plastics & Devices Division


The Plastics & Devices division reported revenues of €294.5 million, reflecting a 14.0% rise, largely due to the inclusion of Bormioli Pharma. On an organic basis, however, the segment experienced a decline of 3.3% compared to the pro forma figures of Q1 2024, attributing this shift to a delay in syringe revenues now expected in the latter half of the financial year. The adjusted EBITDA in this segment grew by 7.0%, totaling €63.4 million, although it was still 11.4% below the previous year's pro forma figures.

Primary Packaging Glass Division


In the Primary Packaging Glass segment, revenues reached €227.1 million, a 9.0% increment due to Bormioli Pharma’s integration. In organic terms, revenues dropped 10.2%, primarily driven by lower demand within the cosmetic industry. Adjusted EBITDA here increased by 15.4% to €40.2 million, showcasing a rise in their EBITDA margin to 17.7% as a result of a more favorable product mix.

Forward-Looking Guidance



Gerresheimer's commitment to sustainable growth is evidenced by the positive reception of existing contracts and increased production ramp-ups anticipated throughout 2025. The overall outlook for the company shows a steady growth trajectory, particularly in segments related to biologics and the launch of new operational lines from ongoing growth initiatives.

In summary, Gerresheimer is not only bouncing back after incorporating Bormioli Pharma but is also strategically positioning itself for a robust future filled with potential. With consistent investment in high-value solutions and innovative systems aimed at biological products, they are set to navigate the changing dynamics of the healthcare market successfully. The financial expectations for the fiscal year 2025 further affirm their commitment to achieving sustained growth and maintaining a solid operational framework as they move ahead.

Topics Business Technology)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.